Molecular cytogenetic analysis by genomic hybridization to determine the cause of recurrent miscarriage
Objective
To characterize a t(2;6) by array-based comparative genomic hybridization (array-CGH) in a couple with recurrent miscarriage, to analyze the meiotic segregation of the t(2;6), and to discuss couple specific care-taking modality before intracytoplasmic sperm injection.
Design
Case report.
Setting
INSERM U613 in Brest, France.
Patient(s)
Couple consulting for infertility.
Intervention(s)
Array-CGH to characterize a t(2;6) and fluorescence in situ hybridization (FISH) to analyze the meiotic segregation were performed.
Main Outcome Measure(s)
Array-CGH, FISH with a panel of bacterial artificial chromosome clones and commercial probes.
Result(s)
Analyses from peripheral blood lymphocytes identified a t(2;6)(q35;q24) unbalanced reciprocal translocation with microdeletions on the der(2) and the der(6). FISH on spermatozoa found that the frequency of normal (23,X or 23,Y) or “translocation-deletions” (23,X,der(2),der(6) or 23,Y,der(2),der(6)) spermatozoa was 41.10%.
Conclusion(s)
For our 46,XY,t(2;6)(q35;q24) carrier, more than 50% of the spermatozoa are chromosomally unbalanced. Moreover, FISH does not permit a distinction between normal and “translocation-deletion” phenotypes. So, in the possibility of preimplantation genetic diagnosis, is it necessary to select the normal embryos to the detriment of those translocation-deletions carriers? The pathogenicity of these microdeletions not been proved. Because the family history was oriented toward a variation of genetic equipment without phenotypic consequences, the couple decided not to make a selection between the normal embryos and the translocation-deletion carrier embryos.
Key Words: Microdeletion, array-CGH, meiotic segregation, recurrent miscarriage, translocation
To access this article, please choose from the options below
A.P. has nothing to disclose. B.D. has nothing to disclose. J.A. has nothing to disclose. P.G. has nothing to disclose. N.G has nothing to disclose. F.P. has nothing to disclose. M.D.B. has nothing to disclose. F.M. has nothing to disclose.
PII: S0015-0282(09)04045-X
doi:10.1016/j.fertnstert.2009.11.016
© 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

